Amendments to the Claims

1-37. Cancelled.

38. (Currently amended): A compound of Formula I



(I)

wherein:

A ~~H-(Q)p-; Q~~ is independently selected~~, each time taken,~~ from the group amino acyl derived from an amino acid selected from the group consisting of:

natural amino acids and

unnatural amino acids, said unnatural amino acids being selected from the group consisting of: the D-isomers of the natural α-amino acids, aminobutyric acid, 3-aminoisobutyric acid, norvaline, βAla, 2-aminoadipic acid, 3-aminoadipic acid, 2-aminobutyric acid, γ-aminobutyric acid, 6-aminocaproic acid, 2,4-diaminobutryic acid, α -aminopimelic acid, trimethylsilyl-Ala, allo-isoleucine, norleucine, tert-Leu, citrulline, Orn, 2,2'-diaminopimelic acid, 2,3-diaminopropionic acid, α - or β-Nal, cyclohexyl-Ala, hydroxyproline, sarcosine, O-methyl tyrosine, phenyl glycine, cyclic amino acids, MeGly (N^{α}-methylglycine), EtGly (N^{α}-ethylglycine) and EtAsn (N^{α}-ethylasparagine), and amino acids in which the α-carbon bears two side-chain substituents;

~~p is an integer from 1 to 10;~~

X is ~~O,~~ S~~, SO,~~ or SO_2~~, or CR^3R^4~~;

~~R^3 is fluoro, X'OR^5, SO_3H, tetrazol-5-yl, CN, $PO_3R^6{}_2$, hydroxy, NO_2, N_3, $(CH_2)_mCOOR^{5a}$, $(CH_2)_mPO_3R^{6a}{}_2$, $NHCONHR^{5b}$, or $NHSO_2R^{5c}$ and R^4 is hydrogen; or R^3 and R^4 each represent fluoro; or R^3 and R^4 together represent =O, =NOR^7, =CR^8R^9, =$CHCOOR^{5b}$, =$CHPO_3R^{6a}{}_2$, or =CHCN; or one of R^3 or R^4 represents amino and the other represents carboxyl;~~

~~X' represents a bond, CH_2, or CO;~~

~~m is an integer from 1 to 3;~~

~~R^5, R^{5a}, R^{5b}, R^{5c}, R^7, R^8, and R^9 are independently a hydrogen atom; an optionally substituted (1-6C) alkyl group; an optionally substituted (2-6C) alkenyl group; an optionally substituted (2-6C) alkynyl group; an optionally substituted aromatic group; an optionally substituted heteroaromatic group; a non-aromatic carbocyclic group; a non-aromatic heterocyclic group; a non-aromatic monocyclic carbocyclic group fused with one or two monocyclic aromatic or heteroaromatic groups; or a non-aromatic monocyclic heterocyclic group fused with one or two monocyclic aromatic or heteroaromatic groups;~~

~~R^6 and R^{6a} independently represent hydrogen or a (1-6C)alkyl group;~~

R^{10} is hydrogen or fluoro; and

R^{11} is hydrogen, fluoro, or hydroxy;

or a pharmaceutically acceptable salt thereof.

39. (Cancelled)

40. (Cancelled)

41. (Cancelled)

42. (Currently amended): A compound or salt according to Claim 38 wherein ~~Q~~ A is an amino acyl derived from a natural amino acid.

43. (Currently amended): A compound or salt according to Claim ~~39~~ 42 wherein ~~Q~~ A is ~~an amino acyl derived from a natural amino acid~~ glycyl, alanyl, valyl, leucyl, isoleucyl, prolyl, phenylalanyl, tyrosyl, tryptophyl, methionyl, lysyl, or serinyl.

44. (Currently amended): A compound or salt according to Claim ~~40~~ 43 wherein ~~Q~~ A is ~~an amino acyl derived from a natural amino acid~~ methionyl.

45. (Currently amended): A compound or salt according to Claim ~~41~~ 44 wherein ~~Q is an amino acyl derived from a natural amino acid~~ R^{10} is hydrogen.

46. (Currently amended): A compound or salt according to ~~any one of Claims 38-45~~ Claim 45 wherein ~~X is SO_2~~ R^{11} is hydrogen.

47. (Cancelled)

48. (Cancelled)

49. (Previously presented): A pharmaceutically acceptable salt according to Claim 38 that is an acid-addition salt made with an acid which provides a pharmaceutically acceptable anion; a base-addition salt made with a base which provides a pharmaceutically acceptable anion for a compound which contains an acidic moiety; or a zwitterionic compound which contains oppositely charged groups.

50. (Currently amended): A compound according to Claim 38 wherein

A is ~~H-(Q)$_p$-~~;

~~Q is~~ L-alanyl;

~~p is 1;~~

X is SO_2 ~~or CR^3R^4~~;

~~R^3 is fluoro and R^4 is hydrogen;~~

R^{10} is hydrogen; and

R^{11} is hydrogen;

or the hydrochloride salt, tosylate salt, mesylate salt, esylate salt, besylate salt, or monosodium salt thereof.

51. (Previously presented): The pharmaceutically acceptable salt according to Claim 50 which is (1*R*,4*S*,5*S*,6*S*)-4-(2'*S*-Aminopropionyl)amino]-2,2-dioxo-2λ^6-thia-bicyclo[3.1.0.]hexane-4,6-dicarboxylic acid hydrochloride or (1*R*,4*S*,5*S*,6*S*)-4-(2'*S*-2'-Aminopropionyl)amino-2,2-dioxo-2λ^6-thia-bicyclo[3.1.0.]hexane-4,6-dicarboxylic acid tosylate.

52. (Previously presented): The compound according to Claim 38 which is (1*R*,4*S*,5*S*,6*S*)-4-(2'S-4'-methylthio-2'-aminobutanonyl)amino-2,2-dioxo-2λ^6-thia-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid or a pharmaceutically acceptable salt thereof.

53. (Previously presented): The compound according to Claim 52 which is (1*R*,4*S*,5*S*,6*S*)-4-(2'*S*-4'-methylthio-2'-aminobutanonyl)amino-2,2-dioxo-2λ^6-thia-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid monohydrate.

54. (Cancelled)

55. (Cancelled)

56. (Cancelled)

57. (Cancelled)

58. (Cancelled)

59. (Previously presented): A process for preparing a compound of Formula I, or a pharmaceutically acceptable salt thereof, as claimed in Claim 38 comprising acylating a compound of formula (ii)



(ii)

with a corresponding amino acyl of Formula III

$$Pg^N\text{-A-} \qquad \text{(III)}$$

wherein Pg^N is a nitrogen-protecting group;

whereafter, for any of the above procedures, when a functional group is protected using a protecting group, removing the protecting group;

whereafter, for any of the above procedures: when a pharmaceutically acceptable salt of a compound of Formula I is required, reacting the basic form of such a compound of Formula I with an acid affording a pharmaceutically acceptable counterion; or for a compound of Formula I

which bears an acidic moiety, reacting the acidic form of such a compound of Formula I with a base which affords a pharmaceutically acceptable cation; or for a zwitterionic compound of Formula I, neutralizing the acid-addition salt form or base-addition salt form of such a compound of Formula I; or by any other conventional procedure.

60. (Cancelled)

61. (Cancelled)

62. (Cancelled)

63. (Cancelled)

64. (Cancelled)

65. (Cancelled)

66. (Currently amended): A method for treating a neurological disorder in a patient which comprises administering to the patient in need of treatment thereof a pharmaceutically-effective amount of a compound of Claim 38 ~~The method of Claim 64~~ wherein said neurological disorder is cerebral deficits subsequent to cardiac bypass and grafting; cerebral ischemia; spinal cord trauma; head trauma; Alzheimer's Disease; Huntington's Chorea; amyotrophic lateral sclerosis; AIDS-induced dementia; perinatal hypoxia; hypoglycemic neuronal damage; ocular damage and retinopathy; cognitive disorders; idiopathic and drug-induced Parkinson's Disease; muscular spasms; migraine headaches; urinary incontinence; drug tolerance, withdrawal, cessation, and craving; smoking cessation; emesis; brain edema; chronic pain; sleep disorders; convulsions; Tourette's syndrome; attention deficit disorder; and tardive dyskinesia.

67. (Cancelled)

68. (Currently amended): The method of Claim 66 ~~or 67~~ wherein said neurological disorder is drug tolerance, withdrawal, cessation, and craving; or smoking cessation.

69. (Cancelled)

70. (Cancelled)

71. (Currently amended): A method for treating a psychiatric disorder in a patient which comprises administering to the patient in need of treatment thereof a pharmaceutically-effective amount of a compound of Claim 38 ~~The method of claim 69~~ wherein said psychiatric disorder is schizophrenia, anxiety and related disorders, depression, bipolar disorders, psychosis, and obsessive compulsive disorders.

72. (Cancelled)

73. (Currently amended): The method ~~according to any one of Claims 71 or 72~~ of Claim 71 wherein said psychiatric disorder is anxiety and related disorders.

74. (Currently amended): A pharmaceutical formulation comprising in association with a pharmaceutically acceptable carrier, ~~dilutent~~ diluent or excipient, a compound of Formula I, or a pharmaceutically acceptable salt thereof.

75. (New): The method of Claim 71 wherein said psychiatric disorder is schizophrenia.